ClinicalTrials.gg
Active, not recruitingNCT03875235TOPAZ-1Updated Aug 26, 2026Results posted

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

A Phase 3 interventional study of Durvalumab and Placebo in Biliary Tract Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 126 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing durvalumab in Biliary Tract Neoplasms — 5 open to participants now, 11 under way, 2 of them phase 3. durvalumab · Biliary Tract Neoplasms.

Enrollment
Largest of 16
810 · median 50
Started
2019
the only one that year
Phase 3
3 of 16
none open now
Primary completion
2021-08
later than 1 of 10 live
Registered
4th of 16
by date
Lead sponsor
4 of 16
AstraZeneca

Among the 16 studies testing durvalumab in Biliary Tract Neoplasms, this one has the largest enrollment, is the only one that started in 2019, is one of 3 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 4th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

5 of the 16 studies testing durvalumab in Biliary Tract Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing durvalumab in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).

Read the detailed description

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers.

03

Conditions studied

  • Biliary Tract Neoplasms

Keywords

  • First-Line Advanced Biliary Tract Cancers (BTC)
  • Durvalumab
  • Gemcitabine/Cisplatin
  • Placebo
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed, unresectable advanced or biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma.
  2. Patients with previously untreated disease if unresectable or metastatic at initial diagnosis will be eligible.
  3. Patient with recurrent disease >6 months after curative surgery or >6 months after the completion of therapy (chemotherapy and/or radiation) will be eligible.
  4. PS of 0 or 1

Exclusion criteria

Exclusion

  1. History of another primary
  2. or spinal cord compression
  3. Uncontrolled intercurrent illness
  4. Major surgical procedure within 28 days prior to the first dose of IP.
  5. Prior locoregional therapy such as radioembolization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Durvalumab + Gemcitabine + Cisplatin

    Drug: Durvalumab

  • Placebo comparator
    Placebo Arm

    Placebo + Gemcitabine + Cisplatin

    Drug: Placebo

Interventions

  • IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.

  • DrugPlacebo

    IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

    Time frame: From date of randomization until death due to any cause. Assessed up to maximum of approximately 27 months (from date of randomization to primary analysis data cut-off)

  2. Overall Survival (OS) Rate at 18 Months

    Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

    Time frame: From date of randomization until death due to any cause. Calculated at 18 months using the Kaplan-Meier technique.

  3. Overall Survival (OS) Rate at 24 Months

    Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

    Time frame: From date of randomization until death due to any cause. Calculated at 24 months using the Kaplan-Meier technique.

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Assessed up to maximum of approximately 27 months.

  2. Progression-free Survival (PFS) Rate at 9 Months

    PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Calculated at 9 months using the Kaplan-Meier technique.

  3. Progression-free Survival (PFS) Rate at 12 Months

    PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Calculated at 12 months using the Kaplan-Meier technique

  4. Objective Response Rate (ORR)

    Disease assessments based on investigator assessments were determined by using RECIST version 1.1 guidelines. The ORR was defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR). The CR was defined as disappearance of all target and non-target lesions and no new lesions. The PR was defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR was defined as 2 CRs or 2 PRs with no evidence of progression in-between. Patients who discontinued randomized treatment without progression, received a subsequent anti-cancer therapy and then responded were not included as responders for ORR.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.

  5. Duration of Response (DoR)

    The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.

  6. Duration of Response (DoR): Percentage Remaining in Response at 9 Months

    The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Calculated at 9 months using the Kaplan-Meier technique

  7. Duration of Response (DoR): Percentage Remaining in Response at 12 Months

    The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Calculated at 12 months using the Kaplan-Meier technique

  8. Disease Control Rate (DCR) - Overall

    Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.

  9. Disease Control Rate (DCR) - 24 Weeks

    Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 24 or who have stable disease (SD) at least 24 weeks following start of treatment.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization.

  10. Disease Control Rate (DCR) - 32 Weeks

    Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 32 or who have stable disease (SD) at least 32 weeks following start of treatment.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter.

  11. Disease Control Rate (DCR) - 48 Weeks

    Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 48 or who have stable disease (SD) at least 48 weeks following start of treatment.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter.

07

Results

Posted Apr 13, 2023

Participant flow

The study is active, not recruiting and conducted in 17 countries with 685 patients who were randomized prior to or on 18 December 2020. Results are reported for the study at data cut-off (DCO) 28 February 2025.

Participant flow — Overall Study
MilestoneDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Started341344
Treated338342
Completed00
Not completed341344
Withdrew: Ongoing study treatment70
Withdrew: Off treatment178
Withdrew: Withdrawal by subject68
Withdrew: Death308326
Withdrew: Lost to follow-up31
Withdrew: Re-consent refusal01

Outcome measures

PrimaryOverall Survival (OS)

Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

Time frame:
From date of randomization until death due to any cause. Assessed up to maximum of approximately 27 months (from date of randomization to primary analysis data cut-off)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Overall Survival (OS)12.8 (11.1 to 14.0)11.5 (10.1 to 12.5)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin · Log Rank · p = 0.021 (The analysis was performed using a stratified log-rank test adjusting for disease status (initially unresectable versus recurrent) and primary tumor location (IHCC versus EHCC versus GBC), and tested at 0.03 significance level.) · Hazard ratio (hr): 0.80 · 97% CI 0.64 to 0.99The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for disease status and primary tumor location.
PrimaryOverall Survival (OS) Rate at 18 Months

Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

Time frame:
From date of randomization until death due to any cause. Calculated at 18 months using the Kaplan-Meier technique.
Reported as:
Number · Percentage of Participants
Overall Survival (OS) Rate at 18 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Overall Survival (OS) Rate at 18 Months35.1 (29.1 to 41.2)25.6 (19.9 to 31.7)
PrimaryOverall Survival (OS) Rate at 24 Months

Overall Survival (OS) was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The second interim analysis was pre-specified after approximately 397 OS events occurred in both arms (59% maturity).

Time frame:
From date of randomization until death due to any cause. Calculated at 24 months using the Kaplan-Meier technique.
Reported as:
Number · Percentage of Participants
Overall Survival (OS) Rate at 24 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Overall Survival (OS) Rate at 24 Months24.9 (17.9 to 32.5)10.4 (4.7 to 18.8)
SecondaryProgression-free Survival (PFS)

PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Assessed up to maximum of approximately 27 months.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Progression-free Survival (PFS)7.2 (6.7 to 7.4)5.7 (5.6 to 6.7)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin · Log Rank · p = 0.001 (The p-value is based on a stratified log-rank test adjusting for disease status (initially unresectable versus recurrent) and primary tumor location (IHCC versus EHCC versus GBC), and tested at 0.0481 significance level.) · Hazard ratio (hr): 0.75 · 95.19% CI 0.63 to 0.89The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for disease status and primary tumor location.
SecondaryProgression-free Survival (PFS) Rate at 9 Months

PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Calculated at 9 months using the Kaplan-Meier technique.
Reported as:
Number · Percentage of Participants
Progression-free Survival (PFS) Rate at 9 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Progression-free Survival (PFS) Rate at 9 Months34.8 (29.6 to 40.0)24.6 (20.0 to 29.5)
SecondaryProgression-free Survival (PFS) Rate at 12 Months

PFS based on investigator assessments according to RECIST version 1.1 was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments every 6 weeks after randomization for the first 24 weeks and then every 8 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Calculated at 12 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of Participants
Progression-free Survival (PFS) Rate at 12 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Progression-free Survival (PFS) Rate at 12 Months16.0 (12.0 to 20.6)6.6 (4.1 to 9.9)
SecondaryObjective Response Rate (ORR)

Disease assessments based on investigator assessments were determined by using RECIST version 1.1 guidelines. The ORR was defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR). The CR was defined as disappearance of all target and non-target lesions and no new lesions. The PR was defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR was defined as 2 CRs or 2 PRs with no evidence of progression in-between. Patients who discontinued randomized treatment without progression, received a subsequent anti-cancer therapy and then responded were not included as responders for ORR.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Objective Response Rate (ORR)26.718.7
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin · Cochran-Mantel-Haenszel · p = 0.011 · Odds ratio (or): 1.60 · 95% CI 1.11 to 2.31OR and CI were estimated from a stratified CMH test adjusting for disease status and primary tumor location.
SecondaryDuration of Response (DoR)

The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.
Reported as:
Median · Months
Duration of Response (DoR)
MonthsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Duration of Response (DoR)6.4 (5.9 to 8.1)6.2 (4.4 to 7.3)
SecondaryDuration of Response (DoR): Percentage Remaining in Response at 9 Months

The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Calculated at 9 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of Participants
Duration of Response (DoR): Percentage Remaining in Response at 9 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Duration of Response (DoR): Percentage Remaining in Response at 9 Months32.625.3
SecondaryDuration of Response (DoR): Percentage Remaining in Response at 12 Months

The DoR was defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments by using RECIST version 1.1 or death in absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1) . A confirmed CR was defined in above outcome measures. The PD was defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. Median DoR was calculated using Kaplan-Meier method.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Calculated at 12 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of Participants
Duration of Response (DoR): Percentage Remaining in Response at 12 Months
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Duration of Response (DoR): Percentage Remaining in Response at 12 Months26.115.0
SecondaryDisease Control Rate (DCR) - Overall

Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD).

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) - Overall
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Disease Control Rate (DCR) - Overall85.382.6
SecondaryDisease Control Rate (DCR) - 24 Weeks

Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 24 or who have stable disease (SD) at least 24 weeks following start of treatment.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization.
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) - 24 Weeks
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Disease Control Rate (DCR) - 24 Weeks57.548.3
SecondaryDisease Control Rate (DCR) - 32 Weeks

Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 32 or who have stable disease (SD) at least 32 weeks following start of treatment.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter.
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) - 32 Weeks
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Disease Control Rate (DCR) - 32 Weeks41.936.3
SecondaryDisease Control Rate (DCR) - 48 Weeks

Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR) or partial response (PR) by week 48 or who have stable disease (SD) at least 48 weeks following start of treatment.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter.
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) - 48 Weeks
Percentage of ParticipantsDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
Disease Control Rate (DCR) - 48 Weeks35.227.0

Adverse events

Collected over Adverse events: from first dose of study medication up to 90 days after the last dose of study medication or until the initiation of the first subsequent therapy (whichever comes first), up to maximum of approximately 67 months. All-cause mortality (death due to any cause): from randomization up to analysis DCO (28 February 2025). Maximum timeframe of approximately 67 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + Gemcitabine + Cisplatin308/341 (90.3%)168/338 (49.7%)326/338 (96.4%)
Placebo + Gemcitabine + Cisplatin326/344 (94.8%)152/342 (44.4%)330/342 (96.5%)
Most frequent serious events
Showing 10 of 197
Most frequent serious events
EventDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
CholangitisHepatobiliary disorders25/33817/342
PyrexiaGeneral disorders15/3388/342
SepsisInfections and infestations12/3389/342
AnaemiaBlood and lymphatic system disorders12/3384/342
Acute kidney injuryRenal and urinary disorders8/3385/342
Biliary obstructionHepatobiliary disorders8/3387/342
PneumoniaInfections and infestations7/3388/342
Abdominal painGastrointestinal disorders1/3388/342
Biliary tract infectionInfections and infestations6/3387/342
Urinary tract infectionInfections and infestations6/3381/342
Most frequent other events
Showing 10 of 45
Most frequent other events
EventDurvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + Cisplatin
AnaemiaBlood and lymphatic system disorders159/338150/342
NauseaGastrointestinal disorders139/338124/342
ConstipationGastrointestinal disorders110/338101/342
NeutropeniaBlood and lymphatic system disorders106/338101/342
Neutrophil count decreasedInvestigations89/338105/342
FatigueGeneral disorders90/33886/342
Decreased appetiteMetabolism and nutrition disorders86/33881/342
Platelet count decreasedInvestigations68/33878/342
PyrexiaGeneral disorders62/33852/342
VomitingGastrointestinal disorders61/33859/342

Baseline characteristics

Baseline analysis was based on all patients in the full analysis set (FAS), which comprised all patients randomized prior to or on 18 December 2020. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received.

Age, Continuous
Age, Continuous(Years)Durvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + CisplatinTotal
Mean62.2 ± 10.4962.6 ± 10.6662.4 ± 10.57
Age, Customized
Age, Customized(Participants)Durvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + CisplatinTotal
Age group (years) — < 65 years181184365
Age group (years) — >=65 - < 75 years122114236
Age group (years) — >= 75 years384684
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + CisplatinTotal
Female172168340
Male169176345
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + Gemcitabine + CisplatinPlacebo + Gemcitabine + CisplatinTotal
Race — American Indian of Alaska Native011
Race — Asian185201386
Race — Black or African American8614
Race — White131124255
Race — Other171229
08

Study locations

126 sites
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Fort Myers, Florida 33905, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Burlington, Massachusetts 01805, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Buenos Aires, C1118AAT, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    CABA, C1019ABS, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1426ANZ, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Burgas, 8000, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Santiago, 7630370, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jinan, 250014, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 100003, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519000, China
  • Research Site
    Clichy, 92210, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nice, 6189, France
  • Research Site
    Paris, 75571, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Hong Kong, 00000, Hong Kong
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Kowloon, Hong Kong
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    New Delhi, 110085, India
  • Research Site
    Faenza, 48018, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Wakayama, 641-8510, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Lodz, 93-513, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Poznan, 60-780, Poland
  • Research Site
    Warsaw, 02-106, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Barnaul, 656049, Russia
  • Research Site
    Kostroma, 156005, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 121467, Russia
  • Research Site
    Moscow, 125284, Russia
  • Research Site
    Omsk, 644033, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Seoul, 152-703, South Korea

Showing the first 100 of 126 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW. Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial. JAMA Oncol. 2026 Jul 9:e262204. doi: 10.1001/jamaoncol.2026.2204. Online ahead of print. PubMed 42424063 ↗
  • Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, Cundom J, Petrova M, Vaccaro G, Holmblad M, Zotkiewicz M, Wang J, Rokutanda N, Oh DY. Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. Oncologist. 2025 Jul 4;30(7):oyaf148. doi: 10.1093/oncolo/oyaf148. PubMed 40622010 ↗
  • Oh DY, He AR, Qin S, Chen LT, Okusaka T, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris HA, Bouattour M, Tanasanvimon S, Zaucha R, Avallone A, Cundom J, Kuzko A, Wang J, Xynos I, Vogel A, Valle JW. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol. 2025 Nov;83(5):1092-1101. doi: 10.1016/j.jhep.2025.05.003. Epub 2025 May 15. PubMed 40381735 ↗
  • Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Zotkiewicz M, Vogel A, Valle JW. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29. PubMed 38823398 ↗
  • Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Zotkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, Oh DY. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024 May;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2. PubMed 38697156 ↗
  • Keller HR, Fluke L, Forrester JA, Wolf RF. Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma. Oncology (Williston Park). 2024 Apr 11;38(4):160-162. doi: 10.46883/2024.25921017. PubMed 38661512 ↗
  • Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1. PubMed 38319896 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2021, 27 months.

Results were first posted in Apr 2023, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 14, 2019
StartActual
Apr 16, 2019
Primary completionActual
Aug 11, 2021
CompletionEst.
May 16, 2027
Results first posted
Apr 13, 2023
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03875235
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 14, 2019
Start date
Apr 16, 2019
Primary completion
Aug 11, 2021
Completion
May 16, 2027 (estimated)
Results posted
Apr 13, 2023
Last update
Aug 26, 2026

Study contacts

Gordon Cohen
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion